Cartesian Therapeutics (RNAC) Net Income towards Common Stockholders (2015 - 2026)

Cartesian Therapeutics (RNAC) has reported Net Income towards Common Stockholders for 12 consecutive years, with -$26.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 31.95% year-over-year to -$26.6 million; the TTM figure through Mar 2026 stood at -$116.5 million (down 76.35% YoY), while the FY2025 annual figure was -$130.3 million, down 68.26% from the prior year.
• Net Income towards Common Stockholders rose to -$26.6 million in Q1 2026 per RNAC's latest filing, from -$78.5 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $13.4 million in Q2 2022 and bottomed at -$196.7 million in Q4 2023.
• Historically, Net Income towards Common Stockholders has averaged -$24.8 million across 5 years, with a median of -$19.2 million in 2023.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders jumped 5275.19% — and 2023, when it tumbled 3437.15%.
• Cartesian Therapeutics' Net Income towards Common Stockholders stood at $5.9 million in 2022, then sank by 3437.15% to -$196.7 million in 2023, then surged by 87.14% to -$25.3 million in 2024, then plunged by 210.45% to -$78.5 million in 2025, then jumped by 66.06% to -$26.6 million in 2026.
• Business Quant data shows RNAC's Net Income towards Common Stockholders at -$26.6 million in Q1 2026, -$78.5 million in Q4 2025, and -$24.6 million in Q3 2025.